Patents by Inventor Vijay T. Ahuja

Vijay T. Ahuja has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOFURAN COMPOUNDS AS STING AGONISTS
    Publication number: 20240109899
    Abstract: The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: BRIAN E. FINK, EMILY CHARLOTTE CHERNEY, LIPING ZHANG, JULIAN C. LO, GRETCHEN M. SCHROEDER, TRAM N. HUYNH, DONNA D. WEI, VIJAY T. AHUJA, CLAUDE A. QUESNELLE
  • URACIL DERIVATIVES AS MER-AXL INHIBITORS
    Publication number: 20230339891
    Abstract: The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 26, 2023
    Inventors: Christine M. Tarby, Derek J. Norris, Julian C. Lo, Vijay T. Ahuja, Steven P. Seitz, Ashvinikumar V. Gavai, John S. Tokarski, Mohini Rajasagi, Michael Wichroski, Matthias Broekema
  • GSK-3 inhibitors
    Patent number: 10774086
    Abstract: The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 15, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Prasanna Sivaprakasam, Gene M. Dubowchik, John E. Macor
  • GSK-3 inhibitors
    Patent number: 10752609
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 25, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Guanglin Luo, Ling Chen, Prasanna Sivaprakasam, Gene M. Dubowchik, Swanee E. Jacutin-Porte, John E. Macor
  • GSK-3 INHIBITORS
    Publication number: 20190315714
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Application
    Filed: November 27, 2017
    Publication date: October 17, 2019
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Guanglin Luo, Ling Chen, Prasanna Sivaprakasam, Gene M. Dubowchik, Swannee E. Jacutin-Porte, John E. Macor
  • GSK-3 INHIBITORS
    Publication number: 20190276463
    Abstract: The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Application
    Filed: November 27, 2017
    Publication date: September 12, 2019
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Prasanna Sivaprakasam, Gene M. Dubowchik, John E. Macor
  • Aryl lactam kinase inhibitors
    Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Quinoline-based kinase inhibitors
    Patent number: 9932320
    Abstract: The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: April 3, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor, Joanne J. Bronson, Bireshwar Dasgupta, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • QUINAZOLINE-BASED KINASE INHIBITORS
    Publication number: 20170239249
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 24, 2017
    Inventors: Richard A. HARTZ, Vijay T. AHUJA, John E. MACOR, Joanne J. BRONSON, Bireshwar DASGUPTA, Carolyn Diane DZIERBA, Susheel Jethanand NARA, Maheswaran Sivasamban KARATHOLUVHU
  • Quinoline-Based Kinase Inhibitors
    Publication number: 20160332985
    Abstract: The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 17, 2016
    Applicant: Bristol-Meyers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor, Joanne J. Bronson, Bireshwar Dasgupta, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA
    Publication number: 20160199372
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: August 12, 2014
    Publication date: July 14, 2016
    Inventors: Richard A. HARTZ, Vijay T. AHUJA, Ramkumar RAJAMANI, Carolyn Diane DZIERBA, Joanne J. BRONSON, John E. MACOR
  • ARYL LACTAM KINASE INHIBITORS
    Publication number: 20160152621
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: July 1, 2014
    Publication date: June 2, 2016
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity
    Patent number: 8436000
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: May 7, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor
  • Pyrazinone modulator of corticotropin-releasing factor receptor activity
    Patent number: 8372847
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: February 12, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • Modulators of G protein-coupled receptor 88
    Patent number: 8304577
    Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: November 6, 2012
    Assignees: Bristol-Myers Squibb Company, Lexicon Pharmaceuticals, Inc.
    Inventors: Carolyn Diane Dzierba, Richard A. Hartz, Yingzhi Bi, Vijay T. Ahuja, Joanne J. Bronson, Kenneth Carson, Giovanni Cianchetta, Michael Green, David Kimball, S. Roy Kimura, Soojin Kwon, John E. Macor, Yulian Zhang, Greg Zipp
  • Modulators of G Protein-Coupled Receptor 88
    Publication number: 20110251196
    Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
    Type: Application
    Filed: October 5, 2010
    Publication date: October 13, 2011
    Inventors: Carolyn Diane Dzierba, Richard A. Hartz, Yingzhi Bi, Vijay T. Ahuja, Joanne J. Bronson, Kenneth Carson, Giovanni Cianchetta, Michael Green, David Kimball, S. Roy Kimura, Soojin Kwon, John E. Macor, Yulian Zhang, Greg Zipp
  • Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity
    Publication number: 20110166160
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 7, 2011
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity
    Publication number: 20110124662
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors.
    Type: Application
    Filed: July 29, 2009
    Publication date: May 26, 2011
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor
  • ()-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
    Patent number: 7932256
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: April 26, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity
    Publication number: 20100029684
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Application
    Filed: April 24, 2009
    Publication date: February 4, 2010
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson